Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 December;178(12) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 December;178(12):911-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2019 December;178(12):911-5

DOI: 10.23736/S0393-3660.18.03974-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Trimetazidine prolongs claudication distance in patients with peripheral arterial disease

Matija KOZAK 1 , Sara MUGERLI 2, Borut JUG 1

1 Department for Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2 General Hospital dr. Franca Derganca, Nova Gorica, Slovenia



BACKGROUND: Intermittent claudication is a common manifestation in peripheral arterial atherosclerotic disease (PAD). Trimetazidine is a metabolic agent with proven anti-ischemic effects in the cardiac muscle. We wanted to assess the effect of trimetazidine as compared to pentoxifylline on pain-free walking distance in symptomatic patients.
METHODS: Stable PAD patients were included in a randomized, open-label, 2-treatment 2-period (2x2) cross-over trial. They were randomized to 4 weeks of trimetazidine (35 mg bid) followed by 4 weeks of pentoxifylline (600 mg bid), or the reversed sequence.
RESULTS: 20 patients (54-79 years) were included. Pain-free and maximal walking distance significantly increased in both groups: 31 m (P=0.002) and 54 m (P=0.001) with trimetazidine, and 32 m (P=0.002) and 27 m (P=0.008) with pentoxifylline, respectively. The difference was statistically not significant with respect to intervention period or intervention sequence.
CONCLUSIONS: Trimetazidine improves pain-free walking distance in symptomatic patients with PAD; the improvement is comparable to pentoxifylline.


KEY WORDS: Peripheral arterial disease; Intermittent claudication; Trimetazidine

inizio pagina